Dishman Carbogen Amcis Limited (NSE:DCAL) informed exchanges on 17 August 2026 that its Management Committee approved the allotment of 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures at a face value of Rs 1,00,000 each, aggregating to Rs 75 crore, issued on a private placement basis.
Key Highlights
- The Management Committee approved allotment of 7,500 NCDs of face value Rs 1,00,000 each at par for cash, aggregating to Rs 75,00,00,000 on 17 August 2026.
- The debentures were issued through private placement, governed by the general information document dated 30 December 2025 and the key information document dated 13 August 2026.
- The final maturity date of the instrument is 17 February 2028, or any earlier redemption date as may be applicable under the disclosed terms.
- The filing was made under Regulations 30, 51, and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
About the Company
Dishman Carbogen Amcis Limited (NSE:DCAL), headquartered in Ahmedabad, Gujarat, is a contract development and manufacturing organisation (CDMO) operating in the pharmaceutical and specialty chemicals sector. The company provides active pharmaceutical ingredient manufacturing, chemical synthesis, and drug development services to global innovator pharmaceutical companies, with manufacturing facilities in India, Europe, and other geographies.
Announcement in Detail
The Management Committee of the Board of Directors convened a meeting on Monday, 17 August 2026, commencing at 12:30 PM and concluding at 1:00 PM. At this meeting, the committee approved the allotment of 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures of face value Rs 1,00,000 each, issued at par for cash consideration. The aggregate issue size amounts to Rs 75,00,00,000 (Rupees Seventy Five Crores), raised on a private placement basis.
The issuance is governed by the terms and conditions set out in the general information document dated 30 December 2025 and the key information document dated 13 August 2026. The date of allotment is confirmed as 17 August 2026, and the final maturity date is 17 February 2028, subject to any early redemption date as prescribed under the applicable terms. The board had originally approved the issue on 12 August 2026, following a prior intimation of the board meeting dated 7 August 2026.
Impact on Investors
Investors will note that this issuance constitutes a debt raise of Rs 75 crore through privately placed NCDs, which adds to the company's outstanding debt obligations. The disclosed maturity date of 17 February 2028 indicates a tenor of approximately eighteen months from the allotment date. The filing shows the debentures are secured and rated, which provides a degree of structural protection to NCD holders, though equity shareholders will observe that servicing this debt will form part of the company's financial commitments through FY28.
The disclosed terms indicate the issuance was conducted at par value with no conversion feature, meaning existing equity shareholders are not subject to dilution from this transaction. Shareholders will observe that the company had sought and obtained prior board approval on 12 August 2026 before proceeding with allotment, consistent with SEBI LODR disclosure norms.
Sector / Market Context
India's CDMO and pharmaceutical outsourcing sector has attracted significant capital in recent years, with domestic manufacturers expanding capacity to service global innovator demand. The Reserve Bank of India's monetary policy stance through 2025-26 has influenced corporate borrowing costs, making rated and secured NCD issuances a commonly used instrument among mid-cap pharmaceutical and specialty chemical companies seeking fixed-tenure debt financing outside the traditional bank lending route. Private placement of NCDs listed on exchanges offers issuers flexibility while providing investors defined redemption timelines.